Ubah, Obinna C.Steven, JohnPorter, Andrew J.Barelle, Caroline J.2019-03-222019-03-222019-03Ubah, O C, Steven, J, Porter, A J & Barelle, C J 2019, 'An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model', Frontiers in Immunology, vol. 10, 526. https://doi.org/10.3389/fimmu.2019.005261664-3224RIS: urn:F2D6899978E05B8509B07A2EE5FEBA44Mendeley: 12816d3c-6ded-3da5-bca3-d680c2133405http://hdl.handle.net/2164/12078Funding The Biotechnology and Biological Sciences Research Council (BB/K010905/1), Scottish Enterprise (VNAR_001 (2012), Innovate UK (102865). Acknowledgments The authors wish to acknowledge the funding support for this work from Scottish Enterprise (SE), the Biotechnology and Biological Sciences Research Council (BBSRC), and Innovate UK.122663845engvariable new antigen receptors (VNARs)chronic inflammationshark IgNARanti-TNF biologicsrheumatoid arthritisautoimmune diseaseTNF-alphaRHEUMATOID-ARTHRITISADALIMUMABTHERAPEUTIC ANTIBODIESKNOCKOUT MICEDOSE-ESCALATIONMURINE MODELIMMUNOGENICITYTUMOR-NECROSIS-FACTORTRANSMEMBRANE TNF-ALPHAMONOCLONAL-ANTIBODIESR Medicine (General)Immunology and AllergyImmunologyInnovate UK102865Biotechnology and Biological Sciences Research Council (BBSRC)BB/K010905/1OtherVNAR_001 (2012)R1Journal article10.3389/fimmu.2019.00526http://www.scopus.com/inward/record.url?scp=85064721344&partnerID=8YFLogxKhttps://www.frontiersin.org/article/10.3389/fimmu.2019.00526/fullhttp://www.mendeley.com/research/antihtnf%CE%B1-variable-new-antigen-receptor-format-demonstrates-superior-vivo-preclinical-efficacy-humir10